![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Bronchopulmonary neuroendocrine tumours (BP-NET) are a heterogeneous population of neoplasms with different pathology, clinical behaviour and prognosis compared to the more common lung cancers. The management of BP-NET patients is largely based on studies with a low level of evidence and extrapolation of data obtained from more common types of neuroendocrine tumours. This review reflects our view of the current state of the art of diagnosis and treatment of patients with BP-NET.
Acknowledgements
Morten Ladekarl: Novartis advisory Board; Henning Grønbæk: Novartis advisory Board, received research grants form Novartis and IPSEN pharmaceutical companies; Ulrich Knigge: Novartis Advisory Board, IPSEN Advisory Board; received research grants form Novartis and IPSEN pharmaceutical companies.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.